ClinicalTrials.govpublic full text
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
hormone-receptor-positive breast cancer, her2-negative breast cancer, metastatic breast cancer, bgb-21447, bgb-43395, bcl-2i, cdk4i, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 905788
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.